Process owners in biopharma manufacturing are concerned about leakages and contamination in single use systems. Annex1 also highlights that manual handling activities associated with single-use systems, such as assembly and connection of components require appropriate controls and must be verified during Aseptic Process Simulation (APS). Where there is a potential risk to product sterility, suitable system integrity testing should be implemented to demonstrate robustness.

Furthermore, Annex 1 emphasizes that closed systems should be intentionally designed to minimize manual interventions and the risks they introduce. Thus, SUS assemblies should be engineered with the minimum number of connections necessary, using robust, well-qualified connection technologies to reduce contamination risk and ensure consistent aseptic performance.
Continue reading “Advancing critical SUS design with Overmolding Technology”

